How UKHSA's Vaccine Development and Evaluation Centre use microneutralisation assays (MNA)

This video provides an insight into how the UK Health Security Agency’s (UKHSA’s) Vaccine Development and Evaluation Centre (VDEC) uses the microneutralisation assay (MNA).
MNA helps evaluate vaccine effectiveness by measuring antibody responses. By testing serum samples from vaccinated individuals, VDEC can predict how well vaccines protect against specific viruses, such as SARS-CoV-2 during the COVID-19 pandemic. It also provides insights into how vaccines may reduce the severity of infection and by assessing neutralizing antibodies, VDEC gains valuable information about potential outcomes in vaccinated individuals.
VDEC collaborates closely with vaccine developers and VDEC scientists run MNAs to assess vaccine candidates, predict protection levels, and inform decision-making during clinical trials. VDEC’s MNA plays a crucial role in understanding vaccine efficacy and guiding public health strategies.
This video, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), is part of the novel and dangerous pathogens training provided by UKHSA.